Product Information

IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $2.8107 per EA under NDC 43598034531. Its NADAC has been published 319 times since Oct 14, 2020.

FDA first approved this application on Aug 13, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

IMATINIB MESYLATE 400 MG TAB

Imatinib
$2.8107per EA

Strength

400 mg/1

NDC

43598034531

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

IMATINIB MESYLATE

Approval Type

Generic (ANDA)

FDA Application

ANDA206547

FDA Approved

8/13/2018

TE Code

AB

On Market Since

8/13/2018

Pharmacological Classes

Bcr-Abl Tyrosine Kinase Inhibitors
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Kinase Inhibitor

Price Statistics

The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 319 times since Oct 14, 2020, and over the history we have for it it has declined 68.5%. The table below summarizes its recorded NADAC range and movement.

Current price$2.8107 per EA
All-time high$8.9088 (Oct 14, 2020)
All-time low$1.4080 (Aug 23, 2023)
52-week high$3.2150
52-week low$2.6771
Median price$2.6827
Average price$2.9505
Largest weekly change-36.2% (Jul 21, 2021)
Weeks tracked319
Tracking sinceOct 14, 2020

Price History

1W

+4.8%

1M

+5.0%

3M

-2.3%

6M

-6.8%

1Y

-6.5%

3Y

+61.8%

5Y

-27.3%

All

-68.5%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 2%

1 alternative • Same active ingredient

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Dr. Reddy's Laboratories Inc., is $2.8107 per EA (NDC 43598034531), effective Nov 18, 2026.

How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?

Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has declined 68.5%. It has been tracked across 319 weekly CMS publications since Oct 14, 2020.

What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?

Since Oct 14, 2020, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $1.4080 (Aug 23, 2023) to a high of $8.9088 (Oct 14, 2020), with a median of $2.6827 per EA.

Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMATINIB MESYLATE 400 MG TAB, is $2.7670 per EA — about 2% below IMATINIB MESYLATE 400 MG TAB.

Who manufactures IMATINIB MESYLATE 400 MG TAB?

IMATINIB MESYLATE 400 MG TAB (NDC 43598034531) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.